pharmaphorum

JANUARY 24, 2022

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. For its part, IBM has said that the Watson for Oncology product has been improving year-on-year as the AI crunches more and more data.

Cerner 110

Cerner 110

Roots Analysis

JANUARY 28, 2024

Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. Within the healthcare sector, structured data includes demographic details, vital indicators (like, height, weight, blood pressure, blood glucose).

Health and Personal Care Stores 40

Health and Personal Care Stores Medical Records Hospitals 40

Pharmaceutical Technology

MAY 1, 2023

CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. Additionally, both the companies will share CTH-004 pre-clinical and clinical data in future.

52

52

pharmaphorum

DECEMBER 17, 2021

Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug’s accelerated approval for controversial Alzheimer’s drug Aduhelm to a full one. The post Biogen updates on its confirmatory Aduhelm trial appeared first on.

FDA 52

FDA 52

Pharmaceutical Technology

DECEMBER 15, 2022

This extrapolation leverages data from GlobalData’s World Markets Healthcare and PharmOnline International databases to expand the number of markets in GlobalData’s patient-based sales forecast model from seven major markets (7MM) to 68 markets (68M). of sales in 2021 and 2031 respectively. of global cardiomyopathies sales in 2021 and 31.2%

52

52

pharmaphorum

DECEMBER 23, 2022

Here, Richard Staines reports on phase I/II data unveiled at the American Society of Hematology conference that supports further clinical development of inobrodib in multiple myeloma and other blood cancers. Oral therapy data presented at ASH. CellCentric, a U.K-based Professional reception of the findings.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

JUNE 8, 2021

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” — Dr. Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021.

FDA 98

FDA Labelling 98

pharmaphorum

NOVEMBER 16, 2021

“We look forward to the full technology appraisal guidance (TAG) which is due to be published in early December 2021,” he added. An opinion from the Scottish Medicine Consortium (SMC) on the use of the drug by NHS Scotland is expected to be published early in 2022.

Documentation 91

Documentation 91

Pharmaceutical Technology

MAY 2, 2023

Combining data from all markets, efficacy-related needs were identified as the most important unmet needs category. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. Cost-related unmet needs also scored highly.

Immunization 52

Immunization Vaccines 52

pharmaphorum

APRIL 27, 2022

The coveted status has been awarded to the HER2-targeting antibody-drug conjugate (ADC) on the back of the DESTINY-Breast04 trial results, unveiled in February, which involved patients with HER2-low, unresectable and/or metastatic breast cancer previously treated with one to two prior lines of chemotherapy.

Chemotherapy 58

Chemotherapy FDA 58

Pharmaceutical Technology

JUNE 29, 2022

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

MAY 10, 2022

As with Aduhelm (aducanumab), lecanemab is being filed via the accelerated approval pathway, with the companies seeking a green light on the strength of the results of a phase 2b trial ahead of the readout of the confirmatory Clarity AD trial, due in the autumn.

FDA 40

FDA 40

pharmaphorum

JULY 25, 2022

It showed an overall response rate with Tecvayli of 63%, including 39% complete responses which is a remarkable result given that the patient recruited into the trial were very ill and heavily pre-treated. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

FDA 52

FDA 52

pharmaphorum

NOVEMBER 24, 2022

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up. The post J&J builds case for antidepressant Spravato with head-to-head trial appeared first on.

Labelling 52

Labelling Hospitals 52

pharmaphorum

MAY 17, 2021

Empaveli’s label covers treatment-naïve PNH patients as well as those who want to switch from Soliris or Ultomiris, and is based on the phase 3 PEGASUS trial in 80 patients which compared the drug to Soliris over a 16-week period. In that study, patients in the Empaveli group saw an average increase of 2.4 billion and $1.1

FDA 52

FDA Labelling Vaccines 52

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Immunization 52

Immunization 52

The Checkup by Singlecare

DECEMBER 5, 2023

The #ozempic tag on TikTok has amassed over 1 billion views to date. Using SingleCare data, we have found the states where Ozempic is most popular. Ozempic became one of the most talked about drugs in 2023. Elon Musk posted his endorsement of Ozempic on X. Jimmy Kimmel joked about it in his monologue at the 2023 Oscars.

Insurance 105

Insurance Prescription Filling FDA Dosage 105

pharmaphorum

AUGUST 18, 2022

” In clinical trials of the gene therapy, 89% of 41 patients remained free of the need for blood transfusions after a median of 42 months’ follow-up. An FDA advisory committee recommended approval of Zynteglo on the strength of that data in June. bluebird has opted to launch it at a cost of $2.8

FDA 52

FDA Insurance 52

PharmD Live

DECEMBER 21, 2021

Aduhelm was approved by the FDA in 2021 with clinical trials outcome data indicating the potential to slow the accumulation of amyloid plaques. With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag. Aduhelm earns FDA approval.

FDA 52

FDA Hospitals 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. And my estimate is that between 25,000 and 30,000 patients have been treated with those therapies globally, which does not include patients treated in clinical trials.

FDA 59

FDA Immunization 59

The Checkup by Singlecare

NOVEMBER 2, 2023

If a drug is FDA approved for a particular purpose, that means the Food and Drug Administration (FDA) has deemed the drug to be effective for that purpose, based on reviewing extensive data from clinical trials supporting its use. A 2020 clinical trial demonstrates this point. This includes Medicare and Medicaid.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

Viseven

NOVEMBER 30, 2022

From AI-based drug discovery to running virtual cohorts for clinical trials or doing continuous manufacturing instead of batch manufacturing, from launching a project effectively to doing real-world tickets, there is technology penetration all along the value chain.

52

52

The Checkup by Singlecare

MARCH 21, 2023

Non-opioids should always be maximized before trialing opioids. Based on the response, opioids may warrant dose titrations as well as trials of different medications within the class to control pain. Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag.

Dosage 52

Dosage Controlled Substances Labelling Packaging 52

PharmaShots

MARCH 9, 2023

An elected member of Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI), she also serves fellow of the American Gastroenterological Association. and medical doctor in clinical pharmacology Other Affiliations: She is a member of the Board of Directors of L’Oréal S.A

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

OCTOBER 4, 2022

Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. The Moonshot was started with three aims: to accelerate scientific discovery in cancer, foster greater collaboration between stakeholders, and to improve the sharing of cancer data.

Documentation 99

Documentation Data Entry HIPAA Insurance 99

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Despite this, the Institute for Clinical and Economic Review (ICER) claimed that a fairer price would be in the region of $2.9m.

FDA 98

FDA 98

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. And 65% of pharma sales rep meetings were held virtually.

Vaccines 90

Vaccines 90

pharmaphorum

DECEMBER 2, 2020

The FDA had already granted fast-track designation to the combination therapy, allowing extra help during the development process on the basis of earlier clinical data. TG said it expects the data submission to be complete in the first half of 2021.

FDA 52

FDA Chemotherapy 52

pharmaphorum

DECEMBER 7, 2021

Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a lower risk of developing Alzheimer’s disease – a link that they say should be examined more closely in clinical trials. Sildenafil is also sold as Revatio to treat pulmonary artery hypertension (PAH).

Compounding 52

Compounding Insurance FDA 52

Viseven

FEBRUARY 6, 2023

In addition, AI-driven software attracts pharma companies that study its potential in new drug discovery, patient diagnostics automation, and clinical trials which is great for recruitment campaigns.

Communication 75

Communication 75

The Checkup by Singlecare

JUNE 21, 2023

The condition causes higher levels of androgen hormone production, resulting in symptoms such as irregular menstrual cycles, acne, excess hair growth, cysts, skin tags, thinning hair, skin darkening, and infertility. But she says that other GLP-1 RAs have more data to support their use as weight loss drugs.

Insurance 98

Insurance FDA Compounding Compounding Pharmacies 98

European Pharmaceutical Review

DECEMBER 27, 2023

2,3 Clinical implementation of CAR T-cell technology requires a reproducible T-cell manufacturing platform, which necessitates effective gene-transfer tools and T-cell culture conditions. 6-8 Clinical recommendations also change. This is in addition to its considerable price tag.

Adverse Reactions 86

Adverse Reactions Immunization Medical Schools Chemotherapy 86

Pharmaceutical Technology

NOVEMBER 30, 2022

Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. More data needed.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. More data needed.

Insurance 98

Insurance Labelling Communication FDA 98

Pharma Marketing Network

JUNE 8, 2020

There’s what I call the real market and so this market really exploded, and I have data in this chapter about it. But I guess to be a bit of a contrarian and backed up with a lot of data. You better get people to a Virginia Mason or a Mayo Clinic or things like that. I mean Mayo Clinic, they found about 20% misdiagnosis.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40